Predictive markers in the adjuvant therapy of non-small cell lung cancer

MiRNA-21

“…[25][26][27][28][29][30][31][32][33][34][35][36][37][38][39] These researchers also showed the high stability of circulating miRNAs after RNase digestion and other harsh conditions such as boiling, extremes of pH, extended storage and freezethaw cycles. Thus, the high stability characteristics of circulating miRNAs would potentially provide advantages as biomarkers when compared with those of other nucleic acids, such as circulating DNA and mRNA.…”

Excision repair cross complementation group 1 is a chemotherapy-tolerating gene in cisplatin-based treatment for non-small cell lung cancer

“…variations with platinum-based chemotherapy response and resistance (30)(31)(32)(33). Although an exact conclusion has not been made due to the differences of these studies in trial design and laboratory tests (24,34), ERCC1 has attracted great attention of the NSCLC investigators. Studies are underway to determine further correlations between ERCC1 and platinumbased chemotherapy, as well as the underlying mechanisms of platinum resistance in NSCLC treatment (12).…”

“…It is still controversial whether ERCC1 should be used as a predictor to guide clinical personalized chemotherapy or not, due to the inconsistence of clinical outcomes (24). Multicenter clinical trails with larger sample size, such as the International Adjuvant Lung Cancer Trial biologic Program (IALT-bio) and the Lung Adjuvant Cisplatin Evaluation biologic Program (LACE-Bio) (25)(26)(27), should be conducted for the application of ERCC1 in clinic.…”

Serum IL-33 as a Diagnostic and Prognostic Marker in Non-small Cell Lung Cancer

“…Screening for early NSCLC predictive biomarkers is a key tool to establish the early diagnosis, which holds promise to further improve the outcome (Filipits et al, 2011). However, the existing biomarkers and predictors for NSCLC are not satisfying due to lack of adequate sensitivity and specificity (Indovina et al, 2011).…”